The Food and Drug Administration (FDA) has called for efforts to modernise and standardise approaches for the delivery of more effective and safer drugs.
Proteomics is the most applicable technology for implementing biomarker approaches in drug discovery given that virtually all existing drug targets are proteins. Proteomics is a systems based approach for the global study of protein expression changes. It can provide information on gene function, disease processes and mechanisms of drug action at several stages in the drug discovery pipeline and pave the way for improved and faster implementation of drug discovery strategies. Ideally, clinically useful biomarkers should be readily accessible in body fluids such as blood serum or urine.
Research in the CCNR focuses on the following major psychiatric disorders:
- Bipolar Disorder
- Major Depressive Disorder
- Anxiety Disorders
- Autism Spectrum Conditions